Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
30 participants
INTERVENTIONAL
2019-12-10
2022-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)
NCT03883412
Effect of 48 Hours of Treatment With the Natural Peptide-Hormone GLP-1 in Patients With Chronic Heart Failure
NCT00264199
Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes
NCT05478707
Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM Patients
NCT04135287
Semaglutide as an Adjunct to Dieting in the Treatment of Type 2 Diabetes
NCT04854083
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Included patients will be randomized to either 12 weeks of endurance exercise training 3 times a week or therapeutical treatment with semaglutide for 3 months followed by 12 weeks of endurance exercise training 3 times a week. Insulin secretory capacity will be determined by hyperglycemic clamp method before and after.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Semaglutide treatment
3 months of therapeutic semaglutide treatment
Semaglutide
3 months of therapeutic treatment with semaglutide
Semaglutide and Endurance exercise
12 weeks of endurance exercise concomitant to semaglutide treatment
Endurance exercise training
Ergometer cycling at 70 % of VO2 max, 45 minutes, 3 times a week
Semaglutide
3 months of therapeutic treatment with semaglutide
Endurance exercise
12 weeks of endurance exercise
Endurance exercise training
Ergometer cycling at 70 % of VO2 max, 45 minutes, 3 times a week
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Endurance exercise training
Ergometer cycling at 70 % of VO2 max, 45 minutes, 3 times a week
Semaglutide
3 months of therapeutic treatment with semaglutide
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI 28-35
* Moderately preserved insulin secretory capacity (determined by glucagon test)
Exclusion Criteria
* Hypertension grade 3
* Heart disease
* Medical history with pancreatitis
* Diagnosed with neuropathy
* Excessive alcohol consumption
* Any condition that would interfere with the protocol.
40 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Flemming Dela
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Flemming Dela
Role: PRINCIPAL_INVESTIGATOR
University of Copenhagen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Xlab, Center for Healthy Aging, Department of Biomedical Sciences, University of Copenhagen
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Ingersen A, Schmucker M, Alexandersen C, Graungaard B, Thorngreen T, Borch J, Holst JJ, Helge JW, Dela F. Effects of Aerobic Training and Semaglutide Treatment on Pancreatic beta-Cell Secretory Function in Patients With Type 2 Diabetes. J Clin Endocrinol Metab. 2023 Oct 18;108(11):2798-2811. doi: 10.1210/clinem/dgad326.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-19008233
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.